Importance of β-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: Studies with piperacillin- tazobactam and piperacillin-sulbactam

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 4, 1997, Pages 721-727

  Lister, Philip D ^a   Prevan, Andrea M ^a   Sanders, Christine C ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE INHIBITOR; PIPERACILLIN; SULBACTAM; TAZOBACTAM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; DRUG MECHANISM; DRUG POTENCY; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; NONHUMAN; PRIORITY JOURNAL;

EID: 0030891933     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.4.721     Document Type: Article

References (19)

1. Alexov, M., P. D. Lister, and C. C. Sanders. 1996. Efficacy of ampicillinsulbactam is not dependent upon maintenance of a critical ratio between components: sulbactam pharmacokinetics in pharmacodynamic interactions. Antimicrob. Agents Chemother. 40:2468-2477.
2. Blaser, J., B. B. Stone, and S. H. Zinner. 1985. Two compartment kinetic model with multiple artificial capillary units. J. Antimicrob. Chemother. 15(Suppl. A):131-137.
3. Bradford, P. A., C. Urban, A. Jaiswal, N. Mariano, B. A. Rasmussen, S. J. Projan, J. J. Rahal, and K. Bush. SHV-7, a novel cefotaxime-hydrolyzing β-lactamase, indentified in Escherichia coli isolates from hospitalized nursing home patients. Antimicrob. Agents Chemother. 39:899-905.
4. Bush, K., C. Macalintal, B. A. Rasmussen, V. J. Lee, and Y. Yang. 1993. Kinetic interactions of tazobactam with β-lactamases from all major structural classes. Antimicrob. Agents Chemother. 37:851-858.
5. Drusano, G. L., S. C. Schimpff, and W. L. Hewitt. 1984. The acylampicillins: mezlocillin, piperacillin, and azlocillin. Rev. Infect. Dis. 6:13-32.
6. Dudley, M., D. Gilbert, K. Rana, A. Carter, A. Medeiros, and S. Zinner. 1995. Use of an in vitro pharmacodynamic model to determine optimal dose and dosing interval of β-lactamase inhibitor combinations (BLICS), abstr. A63, p. 12. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
7. Eliopolous, G. M., and R. C. Moellering, Jr. 1982. Azlocillin, mezlocillin, and piperacillin: new broad-spectrum penicillins. Ann. Intern. Med. 97:755-760.
8. Fantin, B., B. Pangon, G. Potel, F. Caron, E. Vallee, F. Vallois, J. Mohler, A. Bure, A. Philippon, and C. Carbon. 1990. Activity of sulbactam in combination with ceftriaxone in vitro and in experimental endocarditis caused by Escherichia coli producing SHV-2-like β-lactamase. Antimicrob. Agents Chemother. 34:581-586.
9. Foulds, G. 1986. Pharmacokinetics of sulbactam/ampicillin in humans: a review. Rev. Infect. Dis. 8(Suppl. 5):S503-S511.
10. Jones, R. N., M. A. Pfaller, P. C. Fuchs, K. Aldridge, S. D. Allen, and E. H. Gerlach. 1989. Piperacillin/tazobactam (YTR 830) combinations. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains. Diagn. Microbiol. Infect. Dis. 12:489-494.
11. Leleu, G., M. D. Kitzis, J. M. Vallois, L. Gutmann, and J. M. Decazes. 1994. Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum β-lactamase. Antimicrob. Agents Chemother. 38:195-199.
12. Murray, P. R., H. F. Cantrell, R. B. Lankford, and the In Vitro Susceptibility Surveillance Group. 1994. Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected β-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic gram-positive and gram-negative bacteria. Diagn. Mierobiol. Infect. Dis. 19:111-120.
13. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd ed. Approved standard M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
14. Novick, R. P. 1962. Microiodometric assay of penicillinase. Biochem. J. 83: 236-240.
15. Physicians Desk Reference. 1996. Physicians' Desk Reference. Medical Economics Data, Montvale, N.J.
16. Sanders, C. C., W. E. Sanders, Jr., and E. Smith-Moland. 1986. Characterization of β-lactamases in situ on polyacrylamide gels. Antimicrob. Agents Chemother. 30:951-952.
17. Sanders, W. E., and C. C. Sanders. 1996. Piperacillin/tazobactam: a critical review of the evolving clinical literature. Clin. Infect. Dis. 22:107-123.
18. Sorgel, F., and M. Kinzig. 1993. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J. Antimicrob. Chemother. 31(Suppl. A):39-60.
19. Strayer, A. H., D. H. Gilbert, P. Pvarnik, A. A. Medeiros, S. H. Zinner, and M. N. Dudley. 1994. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection. Antimicrob. Agents Chemother. 38:2351-2356.